Press Releases

Date Title  
Toggle Summary West Pharmaceutical Services, Inc. Announces Fourth Quarter And Full Year 1999 Results
LIONVILLE, Pa., Feb. 15 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced results for the fourth quarter and year-ended December 31, 1999. Sales for the fourth quarter were $115.4 million, compared with $114.8 million reported in the fourth quarter of 1998.
West Pharmaceutical Services, Inc. Announces Fourth Quarter And Full Year 1999 Results
LIONVILLE, Pa., Feb. 15 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced results for the fourth quarter and year-ended December 31, 1999. Sales for the fourth quarter were $115.4 million, compared with $114.8 million reported in the fourth quarter of 1998.
Toggle Summary West Pharmaceutical Services Files IND Application For Nasal Leuprolide For The Treatment Of Endometriosis
LIONVILLE, Pa., Jan. 31 /PRNewswire/ -- West Pharmaceutical Services, Incorporated (NYSE: WST) announced today that it completed filling of an Investigational New Drug (IND) application covering a nasally administered formulation of leuprolide for the treatment of endometriosis and other selected
West Pharmaceutical Services Files IND Application For Nasal Leuprolide For The Treatment Of Endometriosis
LIONVILLE, Pa., Jan. 31 /PRNewswire/ -- West Pharmaceutical Services, Incorporated (NYSE: WST) announced today that it completed filling of an Investigational New Drug (IND) application covering a nasally administered formulation of leuprolide for the treatment of endometriosis and other selected
Toggle Summary West Pharmaceutical Services to Commence Phase I Clinical Trials for Nasal Morphine for Pain
LIONVILLE, Pa., Jan. 18 /PRNewswire/ -- West Pharmaceutical Services, Incorporated (NYSE: WST) announced today that its December 1999 IND (Investigational New Drug) application for a nasally administered formulation of morphine has now passed the FDA 30 day comment period, clearing the way for
West Pharmaceutical Services to Commence Phase I Clinical Trials for Nasal Morphine for Pain
LIONVILLE, Pa., Jan. 18 /PRNewswire/ -- West Pharmaceutical Services, Incorporated (NYSE: WST) announced today that its December 1999 IND (Investigational New Drug) application for a nasally administered formulation of morphine has now passed the FDA 30 day comment period, clearing the way for